In contrast, IFNγ pre-treatment eliminated the ability of tumours to respond to α-PD-1 therapy significantly shortening survival (Fig. 1H–J and Supplementary Fig. 1A–D), indicating that adaptation to IFNγ promotes α-PD-1 therapy resistance. The gene discussed is IFNG; the disease is neoplasm.